REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

Dec 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-12-08

Reporting Person: VAGELOS P ROY (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-08	Common Stock	A	1861	$0.0	Acquired	318669	Direct
2021-10-04	Common Stock	G	347	$0.0	Disposed	141630	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-08	Non-Qualified Stock Option (right to buy)	$644.54	A	21198	Acquired	2031-12-08	Common Stock (21198)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2221	Indirect
Common Stock	37747	Indirect
Common Stock	3609	Indirect

Footnotes

F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Company's common stock.

F2: By trusts for the benefit of nine grandchildren of the reporting person, each of which holds 401 shares of Company stock. The reporting person and/or the spouse of the reporting person is the trustee of each such trust.

F3: The stock option award vests in four equal annual installments, commencing one year after the date of grant.